The highest tertile of METS-IR was associated with a greater hazard of incident cardiovascular disease compared to the lowest tertile (HR 2.05; 95% CI 1.52-2.77).
Cohort (n=2,031)
Does the Metabolic Score for Insulin Resistance (METS-IR) predict incident cardiovascular disease in patients with hypertension and obstructive sleep apnea?
Higher METS-IR scores independently predict an increased risk of incident cardiovascular disease, coronary heart disease, and stroke in patients with hypertension and obstructive sleep apnea.
Effect estimate: HR 2.05 (95% CI 1.52-2.77)
Objective: We aimed to evaluate the METS-IR (metabolic score for insulin resistance) index for the prediction of incident cardiovascular disease (CVD) and its subtypes (coronary artery disease and stroke) in patients with hypertension and obstructive sleep apnea (OSA). Methods: A retrospective cohort study was conducted with 2031 adults with hypertension and OSA, participants from the Urumqi Research on Sleep Apnea and Hypertension study (UROSAH). The hazard ratios and 95% CIs (credibility interval) for CVD and its subtypes were estimated using multivariate Cox proportional hazards regression models. Results: After a median follow-up of 6.80 years (interquartile range: 5.90-8.00 years), a total of 317 (15.61%) participants developed new-onset CVD, including 198 (9.75%) incident coronary heart disease (CHD) and 119 (5.86%) incident stroke. After adjusting for as many relevant confounding factors as possible, each SD increase in METS-IR was associated with a 30% increased risk of new onset overall CVD events, a 32% increased risk of new onset CHD, and a 27% increased risk of new onset stroke. When METS-IR was assessed as tertiles, after adjustment for fully confounding factors, the highest tertiles versus the lowest tertiles were associated with a greater hazard of CVD (HR 2.05; 95% CI 1.52,-2.77), CHD (HR 1.96; 95% CI 1.35-2.84), and stroke (HR 2.24; 95% CI 1.35-3.72). The results of various subgroups and sensitivity analyses were similar. When METS-IR was added, CVD predictions were reclassified and identified more accurately than baseline models for the C-index, continuous net reclassification improvement, and integrated discrimination index. CHD and stroke showed similar results. Conclusion: METS-IR is a powerful predictor of CVD and its subtypes in patients with hypertension and OSA, which can facilitate the identification of high-risk individuals and provide individualized CVD prevention.
Yang et al. (Wed,) conducted a cohort in Hypertension and obstructive sleep apnea (OSA) (n=2,031). METS-IR (metabolic score for insulin resistance) vs. Lowest tertile of METS-IR was evaluated on Incident cardiovascular disease (CVD) (HR 2.05, 95% CI 1.52-2.77). The highest tertile of METS-IR was associated with a greater hazard of incident cardiovascular disease compared to the lowest tertile (HR 2.05; 95% CI 1.52-2.77).